PandemieGrippaleV1, Main, Exploration, bibRecord, 001072

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans

Identifieur interne : 001072 ( Main/Exploration ); précédent : 001071; suivant : 001073

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans

Auteurs : Edgar Turner Overton [États-Unis] ; Paul A. Goepfert [États-Unis] ; Pamela Cunningham [États-Unis] ; William A. Carter [États-Unis] ; Joseph Horvath [États-Unis] ; Diane Young [États-Unis] ; David R. Strayer [États-Unis]

Source :

Vaccine [ 0264-410X ] ; 2014.

RBID : Pascal:14-0246270

Descripteurs français

Pascal (Inist)
- Virus grippal A, Homme, Voie intranasale, Vaccin, IgA, Anticorps, Souche atténuée, Adjuvant immunologique, Muqueuse, Grippe A, Grippe aviaire.
Wicri :
- topic : Homme, Vaccin.

English descriptors

KwdEn :
- Antibody, Attenuated strain, Avian influenza, Human, IgA, Immunological adjuvant, Influenza A, Influenza A virus, Intranasal administration, Mucosa, Vaccine.

Abstract

The intranasal use of rintatolimod, a specific TLR-3 agonist, combined with trivalent seasonal influenza vaccine generated cross-protection against highly pathogenic H5N1 avian influenza in mice. The purpose of this clinical trial is to assess the safety and impact of rintatolimod on intranasal influenza vaccine in healthy adults. During Stage I of this Phase I/II clinical trial, 12 volunteers were immunized intranasally with 3 doses of FluMist® seasonal influenza vaccine on Days 0, 28, and 56 followed by intranasal rintatolimod (50 μg, 200 μg, or 500 μg) 3 days later. Parotid saliva and nasal wash samples were collected at baseline and on Days 25, 53, 84, and 417. The samples were tested for IgA and IgG specific antibodies (Ab) directed against the homologous FluMist® viral hemagglutinins (HAs). In addition, viral specific responses against influenza A HAs were tested for IgA Ab cross-reactivity against 3 H5 clades: HA (H5N1) A/Indonesia/5/2005, HA (H5N1) A/Hong Kong/483/97 and HA (H5N1) A/Vietnam/1194/2004, as well as, two H7 strains, HA (H7N9) A/Shanghai/2/2013 and HA (H7N3) A/chicken/Jalisco/CPA1. The combination of the intranasal FluMist® along with the rintatolimod generated specific secretory IgA responses of at least 4-fold over baseline against at least one of the homologous vaccine strains included in the vaccine in 92% of the vaccinees. Additionally, this vaccination strategy induced cross-reactive secretory IgA against highly pathogenic avian influenza virus strains H5N1, H7N9, and H7N3 with pandemic potential for humans. The combination of rintatolimod and FluMist® was well-tolerated.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000031
to stream PascalFrancis, to step Curation: 001D88
to stream PascalFrancis, to step Checkpoint: 000080
to stream Main, to step Merge: 001081
to stream Main, to step Curation: 001072

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans</title>
<author><name sortKey="Overton, Edgar Turner" sort="Overton, Edgar Turner" uniqKey="Overton E" first="Edgar Turner" last="Overton">Edgar Turner Overton</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Alabama at Birmingham, 908 20th Street South</s1>
<s2>Birmingham, AL 35294</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goepfert, Paul A" sort="Goepfert, Paul A" uniqKey="Goepfert P" first="Paul A." last="Goepfert">Paul A. Goepfert</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Alabama at Birmingham, 908 20th Street South</s1>
<s2>Birmingham, AL 35294</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cunningham, Pamela" sort="Cunningham, Pamela" uniqKey="Cunningham P" first="Pamela" last="Cunningham">Pamela Cunningham</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Alabama at Birmingham, 908 20th Street South</s1>
<s2>Birmingham, AL 35294</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carter, William A" sort="Carter, William A" uniqKey="Carter W" first="William A." last="Carter">William A. Carter</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Hemispherx Biopharma, Inc., One Penn Center, 1617JFK Boulevard, Suite 500</s1>
<s2>Philadelphia, PA 19103</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Horvath, Joseph" sort="Horvath, Joseph" uniqKey="Horvath J" first="Joseph" last="Horvath">Joseph Horvath</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Hemispherx Biopharma, Inc., One Penn Center, 1617JFK Boulevard, Suite 500</s1>
<s2>Philadelphia, PA 19103</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Young, Diane" sort="Young, Diane" uniqKey="Young D" first="Diane" last="Young">Diane Young</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Hemispherx Biopharma, Inc., One Penn Center, 1617JFK Boulevard, Suite 500</s1>
<s2>Philadelphia, PA 19103</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strayer, David R" sort="Strayer, David R" uniqKey="Strayer D" first="David R." last="Strayer">David R. Strayer</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Hemispherx Biopharma, Inc., One Penn Center, 1617JFK Boulevard, Suite 500</s1>
<s2>Philadelphia, PA 19103</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0246270</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0246270 INIST</idno>
<idno type="RBID">Pascal:14-0246270</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000031</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D88</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000080</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000080</idno>
<idno type="wicri:doubleKey">0264-410X:2014:Overton E:intranasal:seasonal:influenza</idno>
<idno type="wicri:Area/Main/Merge">001081</idno>
<idno type="wicri:Area/Main/Curation">001072</idno>
<idno type="wicri:Area/Main/Exploration">001072</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans</title>
<author><name sortKey="Overton, Edgar Turner" sort="Overton, Edgar Turner" uniqKey="Overton E" first="Edgar Turner" last="Overton">Edgar Turner Overton</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Alabama at Birmingham, 908 20th Street South</s1>
<s2>Birmingham, AL 35294</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goepfert, Paul A" sort="Goepfert, Paul A" uniqKey="Goepfert P" first="Paul A." last="Goepfert">Paul A. Goepfert</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Alabama at Birmingham, 908 20th Street South</s1>
<s2>Birmingham, AL 35294</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cunningham, Pamela" sort="Cunningham, Pamela" uniqKey="Cunningham P" first="Pamela" last="Cunningham">Pamela Cunningham</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Alabama at Birmingham, 908 20th Street South</s1>
<s2>Birmingham, AL 35294</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carter, William A" sort="Carter, William A" uniqKey="Carter W" first="William A." last="Carter">William A. Carter</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Hemispherx Biopharma, Inc., One Penn Center, 1617JFK Boulevard, Suite 500</s1>
<s2>Philadelphia, PA 19103</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Horvath, Joseph" sort="Horvath, Joseph" uniqKey="Horvath J" first="Joseph" last="Horvath">Joseph Horvath</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Hemispherx Biopharma, Inc., One Penn Center, 1617JFK Boulevard, Suite 500</s1>
<s2>Philadelphia, PA 19103</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Young, Diane" sort="Young, Diane" uniqKey="Young D" first="Diane" last="Young">Diane Young</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Hemispherx Biopharma, Inc., One Penn Center, 1617JFK Boulevard, Suite 500</s1>
<s2>Philadelphia, PA 19103</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strayer, David R" sort="Strayer, David R" uniqKey="Strayer D" first="David R." last="Strayer">David R. Strayer</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Hemispherx Biopharma, Inc., One Penn Center, 1617JFK Boulevard, Suite 500</s1>
<s2>Philadelphia, PA 19103</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody</term>
<term>Attenuated strain</term>
<term>Avian influenza</term>
<term>Human</term>
<term>IgA</term>
<term>Immunological adjuvant</term>
<term>Influenza A</term>
<term>Influenza A virus</term>
<term>Intranasal administration</term>
<term>Mucosa</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term>
<term>Homme</term>
<term>Voie intranasale</term>
<term>Vaccin</term>
<term>IgA</term>
<term>Anticorps</term>
<term>Souche atténuée</term>
<term>Adjuvant immunologique</term>
<term>Muqueuse</term>
<term>Grippe A</term>
<term>Grippe aviaire</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The intranasal use of rintatolimod, a specific TLR-3 agonist, combined with trivalent seasonal influenza vaccine generated cross-protection against highly pathogenic H5N1 avian influenza in mice. The purpose of this clinical trial is to assess the safety and impact of rintatolimod on intranasal influenza vaccine in healthy adults. During Stage I of this Phase I/II clinical trial, 12 volunteers were immunized intranasally with 3 doses of FluMist® seasonal influenza vaccine on Days 0, 28, and 56 followed by intranasal rintatolimod (50 μg, 200 μg, or 500 μg) 3 days later. Parotid saliva and nasal wash samples were collected at baseline and on Days 25, 53, 84, and 417. The samples were tested for IgA and IgG specific antibodies (Ab) directed against the homologous FluMist® viral hemagglutinins (HAs). In addition, viral specific responses against influenza A HAs were tested for IgA Ab cross-reactivity against 3 H5 clades: HA (H5N1) A/Indonesia/5/2005, HA (H5N1) A/Hong Kong/483/97 and HA (H5N1) A/Vietnam/1194/2004, as well as, two H7 strains, HA (H7N9) A/Shanghai/2/2013 and HA (H7N3) A/chicken/Jalisco/CPA1. The combination of the intranasal FluMist® along with the rintatolimod generated specific secretory IgA responses of at least 4-fold over baseline against at least one of the homologous vaccine strains included in the vaccine in 92% of the vaccinees. Additionally, this vaccination strategy induced cross-reactive secretory IgA against highly pathogenic avian influenza virus strains H5N1, H7N9, and H7N3 with pandemic potential for humans. The combination of rintatolimod and FluMist® was well-tolerated.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Alabama</li>
<li>Pennsylvanie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Alabama"><name sortKey="Overton, Edgar Turner" sort="Overton, Edgar Turner" uniqKey="Overton E" first="Edgar Turner" last="Overton">Edgar Turner Overton</name>
</region>
<name sortKey="Carter, William A" sort="Carter, William A" uniqKey="Carter W" first="William A." last="Carter">William A. Carter</name>
<name sortKey="Cunningham, Pamela" sort="Cunningham, Pamela" uniqKey="Cunningham P" first="Pamela" last="Cunningham">Pamela Cunningham</name>
<name sortKey="Goepfert, Paul A" sort="Goepfert, Paul A" uniqKey="Goepfert P" first="Paul A." last="Goepfert">Paul A. Goepfert</name>
<name sortKey="Horvath, Joseph" sort="Horvath, Joseph" uniqKey="Horvath J" first="Joseph" last="Horvath">Joseph Horvath</name>
<name sortKey="Strayer, David R" sort="Strayer, David R" uniqKey="Strayer D" first="David R." last="Strayer">David R. Strayer</name>
<name sortKey="Young, Diane" sort="Young, Diane" uniqKey="Young D" first="Diane" last="Young">Diane Young</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001072 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001072 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:14-0246270
   |texte=   Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri